Summit Wealth Group’s Bristol-Myers Squibb BMY Stock Holding History

Summit Wealth Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-109,302	Closed	-$2K	–	97
2023 Q1	$2K	Buy	+109,302	New	+$7.71M	0.05%	79

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Summit Wealth Group's BMY Position: Q2 2023 in Review

Summit Wealth Group sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 109,302 shares — an estimated $2K sold.

Summit Wealth Group first reported a position in BMY in Q1 2023 and held it in 1 quarter. The position peaked at $2K in Q1 2023. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

Summit Wealth Group reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
Summit Wealth Group sold 109,302 Bristol-Myers Squibb shares in Q2 2023, an estimated $2K.
Summit Wealth Group first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 1 quarter.
Summit Wealth Group's Bristol-Myers Squibb position peaked at $2K in Q1 2023.
2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on Summit Wealth Group's 13F filing for Q2 2023, filed 26 Jul 2023.